Intraoperative radiofrequency ablation combined with125iodine seed implantation for unresectable pancreatic cancer
Open Access
- 1 January 2010
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 16 (40), 5104-10
- https://doi.org/10.3748/wjg.v16.i40.5104
Abstract
To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer. Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study. The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation. Diagnosis of pancreatic cancer was made through intraoperative biopsy. Patients were treated with FRA combined with (125)iodine seed implantation. In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a (125)iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients. The serum CA 19-9 level was decreased from 512 ± 86 U/mL before operation to 176 ± 64 U/mL, 108 ± 42 U/mL and 114 ± 48 U/mL, respectively, 1, 3 and 6 mo after operation (P < 0.05). The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05). The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo. The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026). The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176). Of the 32 patients, 3 (10.6%) experienced postoperative complications including transient biliary leaks in 2 patients and acute pancreatitis in 1 patient. All the patients recovered well after conservative support treatment. Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.Keywords
This publication has 33 references indexed in Scilit:
- Locally Advanced Pancreatic Cancer: A ReviewSeminars in Oncology, 2007
- Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreasLangenbecks Archiv für Chirurgie, 2006
- Radiofrequency ablation in pancreatic cancerHPB, 2006
- Current role of image-guided ablative therapies in lung cancerExpert Review of Anticancer Therapy, 2005
- A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282International Journal of Radiation Oncology*Biology*Physics, 2005
- Elektivna resekcija slezine - pregled tehnika resekcije i prikaz nove tehnike zasnovane na radiofrekventnoj koagulaciji i desikacijiActa chirurgica Iugoslavica, 2002
- Thoracoscopic Splanchnicectomy for Pain Relief in Unresectable Pancreatic CancerArchives of Surgery, 2000
- Nonparametric estimation of bounded survival functions with censored observations.Lifetime Data Analysis, 1999
- Surgical Palliation for Pancreatic CancerAnnals of Surgery, 1990
- Treatment of primary unresectable carcinoma of the pancreas with I-125 implantationInternational Journal of Radiation Oncology*Biology*Physics, 1989